Keytruda® (pembrolizumab) – Updated indication, accelerated approval converted to full approval
January 25, 2024 - The FDA granted full approval of Merck’s Keytruda (pembrolizumab), for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
Top